Fig. 6: Contribution of GDF15 in the potency of tumor cells and tumor exosomes in inducing muscle atrophy.
From: GDF-15 in tumor-derived exosomes promotes muscle atrophy via Bcl-2/caspase-3 pathway
C2C12 myotubes were treated with MC38-GDF15-OE cell medium, exosomes or C26-GDF15-SH cell medium, exosomes respectively. A Representative immunofluorescent images of C2C12 myotubes treated with MC38-GDF15-OE cell culture medium (scale bars, 50 μm). B Quantification analysis of C2C12 myotubes diameter (n = 546,524,508,401,540, ***p < 0.001; t test). C MHC protein expression analysis via western blot (n = 3, ns p > 0.05, *p < 0.05; t test). D Representative immunofluorescent images of C2C12 myotubes treated with MC38-GDF15-OE cell exosomes (scale bars, 50 μm). E Quantification analysis of C2C12 myotubes diameter (n = 662,960,544,507,507, ***p < 0.001; t test). F MHC protein expression analysis via western blot (n = 3, *p < 0.05; t test). G Representative immunofluorescent images of C2C12 myotubes treated with C26-GDF15-SH cell culture medium (scale bars, 50 μm). H Quantification analysis of C2C12 myotubes diameter (n = 564,539,472,445, ***p < 0.001; t test). I MHC protein expression analysis via western blot (n = 4, *p < 0.05; t test). J Representative immunofluorescent images of C2C12 myotubes treated with C26-GDF15-SH cell exosomes (scale bars, 50 μm). K Quantification analysis of C2C12 myotubes diameter (n = 361,359,361,367, ***p < 0.001; t test). L MHC protein expression analysis via western blot (n = 3, *p < 0.05, **p < 0.01; t test). Data presented are the mean ± SEM.
